Thomas Vanwolleghem

22PUBLICATIONS
76CO-AUTHORS
Nanotoxicology, health and safetyAnimal welfareInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Major global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 26, 2026
Immune Control, HBsAg Loss or Flare Requiring Liver Transplant-Diverse Outcomes After Stopping NUC Therapy.

|Jul 28, 2026
Detection of Infectious Hepatitis E Virus in Retail Pork Pâté After Optimization of Extraction Protocols.

|Apr 23, 2026
Prevalence of hepatitis B surface antibodies and hepatitis B exposure in Belgium: results from a nationwide population-based serosurvey.

|Nov 20, 2025
Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation.

Arno Furquim d'Almeida, Axelle Vanderlinden, Stefan Bourgeois

|Feb 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.

Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal

|Jan 23, 2025
Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.

Arno Furquim d'Almeida, Erwin Ho, Liesbeth Govaerts

Pageof 4

Frequent Collaborators

5 joint publications

Arno Furquim d'Almeida

3 joint publications

Gulce Sari

2 joint publications

Stijn Van Hees

2 joint publications

Markus Cornberg